8-K: Absci Corp. Announces Preliminary 2023 Financials and Business Model Evolution

Absci Corporation released preliminary unaudited financial results for 2023 and detailed a strategic shift in its business model towards a diversified portfolio of partnered and internal drug development programs.

Summary

• Absci Corporation has disclosed preliminary unaudited financial highlights for the three months and year ended December 31, 2023.
• The company estimates having approximately $97.7 million in unrestricted cash and cash equivalents and short-term investments as of December 31, 2023.
• Revenue is expected to be approximately $0.3 million for the three months and $5.7 million for the year ended December 31, 2023.
• Operating expenses are estimated to be between $24 million and $26 million for the quarter and between $120 million and $122 million for the year, including a $21.3 million goodwill impairment recorded in the second quarter.
• These financial results are preliminary and subject to change upon completion of the company's closing procedures and audit.
• Absci is shifting its business model to include both partnered drug creation programs and internal asset development programs.
• The company aims to diversify its portfolio by balancing partnered programs that provide funding and internal programs with greater control and potential for higher returns.
• Absci has 16 active drug creation programs with various partners across different therapeutic areas.
• The company has identified three wholly-owned internal asset programs focusing on cytokine biology, including ABS-101 targeting TL1A for inflammatory bowel disease.
• IND-enabling studies for ABS-101 have commenced in February 2024, with a planned IND submission in the first quarter of 2025 and a potential Phase 1 clinical trial in the first half of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making strategic moves to diversify its portfolio and advance its internal programs, the financial results are weak with high operating expenses and low revenue. The potential capital raise also suggests the company needs additional funding.

Positives

• Absci has a solid cash position of approximately $97.7 million.
• The company is actively engaged in 16 drug creation programs with various partners.
• Absci is developing its own internal pipeline with three wholly-owned programs, including ABS-101 which has shown promising preclinical results.
• The company is diversifying its business model to balance risk and potential return on investment.
• Absci has initiated IND-enabling studies for ABS-101, moving it closer to clinical trials.

Negatives

• The company's revenue is relatively low, with only $0.3 million expected for the quarter and $5.7 million for the year.
• Operating expenses are high, estimated to be between $24 million and $26 million for the quarter and between $120 million and $122 million for the year.
• The company recorded a $21.3 million goodwill impairment in the second quarter of 2023.
• The financial results are preliminary and subject to change.
• There is no guarantee that partners will advance drug candidates or license Absci's technologies.

Risks

• The actual financial results may differ from the preliminary estimates.
• Partners may not advance drug candidates or license Absci's technologies.
• The development of internal programs may face challenges and delays.
• Clinical trials for ABS-101 may not produce similar results to preclinical studies.
• Regulatory approvals for drug candidates are not guaranteed and may be delayed.
• The company's business model evolution may not be successful.

Future Outlook

Absci plans to continue developing its internal pipeline, including advancing ABS-101 to clinical trials, and to expand its partnerships for drug creation. The company aims to balance its portfolio between partnered programs and internal asset development to drive innovation and deliver value for stakeholders.

Management Comments

• The cornerstone of this business model evolution lies in the diversification of risk and potential return on investment.
• We believe we will grow and diversify our portfolio of programs through our model, ultimately driving innovation and delivering value for all stakeholders.

Industry Context

The announcement reflects a trend in the biotechnology industry where companies are increasingly diversifying their pipelines through both internal development and strategic partnerships. Absci's focus on AI-driven drug creation and cytokine biology aligns with current industry interests in innovative drug discovery and development approaches.

Comparison to Industry Standards

• Absci's revenue of $5.7 million for the year is low compared to established biotech companies, which often report tens or hundreds of millions in revenue.
• The operating expenses of $120-122 million are significant, reflecting the high cost of research and development in the biotech sector.
• Companies like Regeneron and Genentech, which have established drug pipelines, have much higher revenue and lower operating expenses as a percentage of revenue.
• Absci's approach of balancing partnered and internal programs is similar to other biotech companies that seek to mitigate risk and maximize potential returns.
• The focus on cytokine biology is a common area of interest for many biotech companies, including Merck, Roche and Sanofi, who are also developing assets targeting TL1A.

Stakeholder Impact

• Shareholders may be concerned about the low revenue and high operating expenses.
• Employees may be impacted by the company's strategic shift and potential changes in priorities.
• Partners may be interested in the company's diversified portfolio and internal programs.
• Customers may benefit from the company's innovative drug creation platform.
• Creditors may be concerned about the company's financial performance.

Next Steps

• Finalize the actual results of operations for the three months and year ended December 31, 2023.
• Submit an IND for ABS-101 in the first quarter of 2025.
• Potentially initiate a Phase 1 clinical trial for ABS-101 in the first half of 2025.
• Continue to develop internal programs and expand partnerships.

Key Dates

Keywords

drug creation, biologics, partnerships, internal pipeline, ABS-101, cytokine biology, financial results, operating expenses, clinical trials, IND, revenue, cash